×
Skye Bioscience Price to Free Cash Flow Ratio 2013-2024 | SKYE
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
Skye Bioscience price to free cash flow ratio from 2013 to 2024. Price to free cash flow ratio can be defined as
View More
Skye Bioscience Price to Free Cash Flow Ratio 2013-2024 | SKYE
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
Skye Bioscience price to free cash flow ratio from 2013 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$155.8B
Bristol Myers Squibb (BMY)
$118.1B
Vertex Pharmaceuticals (VRTX)
$116B
Gilead Sciences (GILD)
$111.9B
CSL (CSLLY)
$86.5B
Regeneron Pharmaceuticals (REGN)
$81.8B
GSK (GSK)
$69.8B
Argenex SE (ARGX)
$35.7B
Alnylam Pharmaceuticals (ALNY)
$31.8B
BioNTech SE (BNTX)
$25.9B
Biogen (BIIB)
$23B
Illumina (ILMN)
$21.7B
BeiGene (BGNE)
$18.9B
Moderna (MRNA)
$14.7B
Incyte (INCY)
$13.6B
Genmab (GMAB)
$13.5B
Insmed (INSM)
$13.2B
BioMarin Pharmaceutical (BMRN)
$12.1B
Bio-Techne Corp (TECH)
$11.3B
Vaxcyte (PCVX)
$11B
Sarepta Therapeutics (SRPT)
$10.6B
Exelixis (EXEL)
$9.9B
Exact Sciences (EXAS)
$9.8B
QIAGEN (QGEN)
$9.7B
Revolution Medicines (RVMD)
$9.6B
Bio-Rad Laboratories (BIO.B)
$9.4B
Intra-Cellular Therapies (ITCI)
$9.1B
Roivant Sciences (ROIV)
$8.7B
Repligen (RGEN)
$7.9B
Ascendis Pharma (ASND)
$7.4B